OLEMA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 147.96 thousand shares for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2023-11-07
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2023-09-30 was 49.32K shares, a 0.00% change year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2023-06-30 was 49.32K shares, a 0.00% change year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2023-03-31 was 49.32K shares, a 0.00% change year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2022-12-31 was 49.32K shares, a 0.00% change year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2022 was 197.27K shares, a 18.52% decline from fiscal 2021.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2021 was 242.11K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month |
|---|---|---|---|---|
| 2023-09-30 | 49.32K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 98.64K shares derived: sum of 2 quarters · filed 2023-11-07 | 147.96K shares 10-Q · filed 2023-11-07 | 197.27K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 49.32K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 98.64K shares 10-Q · filed 2023-08-08 | 147.96K shares derived: sum of 3 quarters · filed 2023-08-08 | 197.27K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 49.32K shares 10-Q · filed 2023-05-09 | 98.64K shares derived: sum of 2 quarters · filed 2023-05-09 | 147.96K shares derived: sum of 3 quarters · filed 2023-05-09 | 197.27K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 49.32K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 98.64K shares derived: sum of 2 quarters · filed 2023-03-09 | 147.96K shares derived: sum of 3 quarters · filed 2023-03-09 | 197.27K shares 10-K · filed 2023-03-09 |
| 2022-09-30 | 49.32K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 98.64K shares derived: sum of 2 quarters · filed 2022-11-08 | 147.96K shares 10-Q · filed 2022-11-08 | 197.27K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 49.32K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 98.64K shares 10-Q · filed 2022-08-09 | 147.96K shares derived: sum of 3 quarters · filed 2022-08-09 | 197.27K shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 49.32K shares 10-Q · filed 2022-05-09 | 98.64K shares derived: sum of 2 quarters · filed 2022-05-09 | 147.96K shares derived: sum of 3 quarters · filed 2022-05-09 | 264.53K shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | 49.32K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 98.64K shares derived: sum of 2 quarters · filed 2022-02-28 | 215.21K shares derived: sum of 3 quarters · filed 2022-02-28 | 242.11K shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 49.32K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 165.89K shares derived: sum of 2 quarters · filed 2021-11-10 | 192.79K shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 116.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 143.47K shares 10-Q · filed 2021-08-10 | ||
| 2021-03-31 | 26.90K shares 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |